BioSpace News Archive

Representing $2 trillion in value, accounting for 15% of total POS transaction value

The awarded paper won the highest scientific merits out of 577 conference papers submitted this year

TransMed7, LLC is delighted to announce the appointment of John B. Simpson, Ph.D., M.D., as Strategic Advisor to the TransMed7 Board of Directors.

Test demonstrated high technical reliability in over 17,000 clinical orders

Centrexion Therapeutics Corporation announced that Nick Harvey has been appointed Chief Financial Officer of the company.

Approval triggers $5 million milestone payment to DURECT and future earn-out payments based on U.S. net sales

Judge Recommends Exclusion Order to Prevent Importation and Cease-and-Desist Order to Prevent Further Sale and Marketing of Infringing Products in the United States

July 30, 2018 12:00 UTC Advaxis Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer Selects Bladder Cancer as Third ADXS-HOT Drug Candidate to Take into the Clinic after Non-Small Cell Lung and Prostate Cancers Advances Goal to Have Five Neoantigen-Based Drug Candidates in Clinical Evaluation by 4Q 2019 PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis,

Arcus Biosciences, Inc. announced that it has received regulatory approval to initiate its Phase 1 trial for AB154

CeraPedics, a privately-held orthobiologics company, today announced that the first patients have been enrolled in an investigational device exemption clinical trial evaluating the safety and efficacy of the next-generation P-15L Peptide Enhanced Bone Graft in transforaminal lumbar interbody fusion surgery.